Intranasal Versus Intravenous Fentanyl For Procedural Analgesia in Preterm Neonates
NCT ID: NCT07190625
Last Updated: 2025-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
75 participants
INTERVENTIONAL
2023-12-24
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Using intranasal fentanyl as an analgesic in preterm neonates may provide a rapid, effective, noninvasive route for administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Intranasal Versus Intravenous Fentanyl in Preterm and Term Newborns for Pain Prevention
NCT02125201
Pain Managment in Preterm Neonates
NCT07148882
Intranasal Fentanyl in Preterm Infants Undergoing Peripherally Inserted Central Catheter Placement
NCT06590870
Continuous Infusion of Fentanyl in Preterm on MV
NCT00571636
Intravenous and Topical Analgesics for Procedural Pain in Neonates
NCT00213200
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Enrolled neonates will be allocated randomly to one of the three groups during painful procedure, using single blinded method, as scoring will occur by a different physician than the researcher.
Atomizer group: will receive intranasal fentanyl (@fentanyl hamein 50 mcg/1 ml, manufactured by Sunny Pharmaceutical) using a nasal atomizer; the dose of INF is 1.5 µg/kg/dose.
Direct nasal group: will receive intranasal fentanyl directly installed into the nostrils with the same dose.
Typically, one dose is given during the procedure; after 5 minutes, a second dose could be administered based on the clinical assessment (maximum two doses per procedure), with reassessment of the pain score.
o Intravenous group: will receive intravenous fentanyl with a dose of 1 μg/kg as the standard of care.
All of the following data will be obtained:
Full history taking: antenatal, natal, and postnatal history Gestational age will be estimated using the date of the last menstrual period and confirmed by the new Ballard scoring system.
Full clinical examination: including general, cardiopulmonary, abdominal, and neurological examinations and anthropometric measurements.
Type of procedure done to the patient, number of attempts if more than once, and number of intranasal fentanyl doses needed.
Type of respiratory support at the time of intranasal fentanyl administration.
Effectiveness of intranasal fentanyl will be assessed using:
Premature Infant Pain Profile (PIPP) scale The pre-procedure PIPP scale will be recorded just before administration of the first dose of IN fentanyl and commencement of the painful procedure, while the post-procedure PIPP score will be recorded within 5 minutes of fentanyl administration.
PIPP scores range from 0 to 21. A PIPP score of 0-6 suggests minimal or no pain, 7-12 indicates moderate pain, and a score ≥ 13 is interpreted as severe pain.
Physiological parameters of heart rate, respiratory rate, oxygen saturation, blood pressure, and fraction of inspired oxygen (FiO2) at baseline (just before fentanyl administration) and at pre-specified intervals (15, 30, 45, and 60 min) after fentanyl use.
Monitor adverse events after fentanyl use, such as apnea (cessation of breathing for \>20 s), bradycardia (heart rate \< 100 beats/minute), desaturation (oxygen saturation \< 80%) , and chest wall rigidity associated with laryngospasm for 60 min after IN fentanyl administration. Local effects include nasal discomfort and irritation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intravenous group
this group of neonates will recieve intravenous fentanyl during procedure
fentanyl intravenous
giving intravenous fentanyl
direct intranasal group
this group of neonates will recieve direct intranasal fentanyl during procedure
fentanyl intranasal direct
giving intranasal fentanyl directly into nostrils
nasal atomizer group
this group of neonates will recieve intranasal fentanyl with atomizer during procedure
Fentanyl intranasal using atomizer
giving intranasal fentanyl using nasal atomizer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fentanyl intravenous
giving intravenous fentanyl
Fentanyl intranasal using atomizer
giving intranasal fentanyl using nasal atomizer
fentanyl intranasal direct
giving intranasal fentanyl directly into nostrils
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing painful procedures such as central venous access insertion, elective endotracheal intubation, and lumbar puncture.
Exclusion Criteria
* Known contraindication for intranasal administration of drugs (choanal atresia, nasal mucosal erosion, and epistaxis)
* Post-surgical patients.
* Patients sedated by fentanyl infusion / midazolam infusion.
* Evidence of neurological disease with disturbed conscious level, such as intraventricular hemorrhage grade III or IV, hypoxic ischemic encephalopathy, or inborn error of metabolism.
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Passant Fahmy, M.Sc
Role: PRINCIPAL_INVESTIGATOR
Assisstant lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Rabab Gameel Allam, MD
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MD342/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.